Fig. 2From: Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC(a) OS analysis of 98 patients stratified by ECOG 0 (n =25) or 1 and 2 (n =73), p =0.02; (b) OS analysis of 98 patients stratified by PD-L1 TPS < 75 (n =46) or ≥ 75 (n =52), p =0,4Back to article page